FilingReader Intelligence
Southern Shuanglin Bio-Pharmacy approves funding, guarantees
March 4, 2025 at 05:14 AM UTC•By FilingReader AI
Southern Shuanglin Bio-Pharmacy (SZSE:000403) has announced the resolutions passed at its 13th Meeting of the 10th Board of Directors, paving the way for strategic financial maneuvers. Directors approved the continued use of up to ¥100 million in idle raised funds to supplement working capital, extending an existing authorization for up to 12 months.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Southern Shuanglin Bio-Pharmacy publishes news
Free account required • Unsubscribe anytime